JP2013535191A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535191A5
JP2013535191A5 JP2013519918A JP2013519918A JP2013535191A5 JP 2013535191 A5 JP2013535191 A5 JP 2013535191A5 JP 2013519918 A JP2013519918 A JP 2013519918A JP 2013519918 A JP2013519918 A JP 2013519918A JP 2013535191 A5 JP2013535191 A5 JP 2013535191A5
Authority
JP
Japan
Prior art keywords
seq
set forth
sequence set
binding protein
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013519918A
Other languages
English (en)
Japanese (ja)
Other versions
JP5972871B2 (ja
JP2013535191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000923 external-priority patent/WO2012009760A1/en
Publication of JP2013535191A publication Critical patent/JP2013535191A/ja
Publication of JP2013535191A5 publication Critical patent/JP2013535191A5/ja
Application granted granted Critical
Publication of JP5972871B2 publication Critical patent/JP5972871B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013519918A 2010-07-20 2011-07-20 抗il−23ヘテロ二量体特異的抗体 Expired - Fee Related JP5972871B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2010903234 2010-07-20
AU2010903234A AU2010903234A0 (en) 2010-07-20 Anti-IL-23 heterodimeric specific antibodies
US38494510P 2010-09-21 2010-09-21
US61/384,945 2010-09-21
PCT/AU2011/000923 WO2012009760A1 (en) 2010-07-20 2011-07-20 Anti-il-23 heterodimer specific antibodies

Publications (3)

Publication Number Publication Date
JP2013535191A JP2013535191A (ja) 2013-09-12
JP2013535191A5 true JP2013535191A5 (enExample) 2014-07-17
JP5972871B2 JP5972871B2 (ja) 2016-08-17

Family

ID=45496377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519918A Expired - Fee Related JP5972871B2 (ja) 2010-07-20 2011-07-20 抗il−23ヘテロ二量体特異的抗体

Country Status (9)

Country Link
US (1) US9127057B2 (enExample)
EP (1) EP2596022A4 (enExample)
JP (1) JP5972871B2 (enExample)
CN (1) CN103108886B (enExample)
AU (1) AU2011282476B2 (enExample)
CA (1) CA2805653A1 (enExample)
MX (1) MX341309B (enExample)
NZ (1) NZ604415A (enExample)
WO (1) WO2012009760A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
ES2711554T3 (es) * 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
GB201214974D0 (en) * 2012-08-22 2012-10-03 Univ Edinburgh Avian proteins, nucleic acids and uses thereof
US9669091B2 (en) * 2013-03-15 2017-06-06 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-23 as an adjuvant
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
CN105209064A (zh) 2013-03-15 2015-12-30 美国安进公司 使用抗il-23抗体治疗银屑病的方法
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途径生物标志物预测il23拮抗剂的临床应答
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
RS66900B1 (sr) 2016-12-21 2025-07-31 Cephalon Llc Antitela koja se specifično vezuju za humani il-15 i njihova upotreba
CA3105598A1 (en) 2018-07-13 2020-01-16 Carl GOMMOLL Treating ulcerative colitis with brazikumab
CN109970855A (zh) * 2019-04-12 2019-07-05 深圳普瑞金生物药业有限公司 Il23单域抗体的vhh链、il23单域抗体、核苷酸序列及试剂盒
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
AU2024349247A1 (en) * 2023-09-27 2026-04-16 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-23 antibody
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
EP0569141A3 (en) 1992-04-14 1994-10-26 Hybritech Inc Method for inhibiting the growth of multidrug-resistant tumors by antibodies.
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
WO2000042430A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド IL−23p40特異的免疫グロブリン由来タンパク質、組成物、方法および用途
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2602709A1 (en) 2005-03-31 2006-10-05 Telethon Institute For Child Health Research Isolation of inhibitor of ires-mediated translation
EP2452694B1 (en) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
WO2007011670A2 (en) 2005-07-15 2007-01-25 Zymogenetics, Inc. Heterodimeric four helix bundle cytokines
JP2009504685A (ja) 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド 新世界霊長類フレームワーク領域を用いる設計された抗体
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20160116056A (ko) * 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-il-12/il-23 항체
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos

Similar Documents

Publication Publication Date Title
Byrne et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
JP2010502183A5 (enExample)
JP2020534830A5 (enExample)
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2014158485A5 (enExample)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
JP2018504890A5 (enExample)
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2018532766A5 (enExample)
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
IL261666B1 (en) Binding proteins and methods of use thereof
JP2013506428A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2017504578A5 (enExample)
JP2016500655A5 (enExample)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2013507115A5 (enExample)
JP2020524510A5 (enExample)
JP2008538289A5 (enExample)
JP2016516400A5 (enExample)
RU2010133547A (ru) Анти-cldn антитела
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2021500916A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение